Analyst Ratings for Tempest Therapeutics
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 5 analysts have published their opinion on Tempest Therapeutics (NASDAQ:TPST) stock, with 4 bullish and 1 somewhat bullish ratings. The average 12-month price target is $25.0, with a high of $35.00 and a low of $6.00. The average price target has increased by 177.78% over the past month.
May 30, 2023 | 7:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tempest Therapeutics (NASDAQ:TPST) has received positive analyst ratings, with an average 12-month price target of $25.0, up 177.78% over the past month.
The positive analyst ratings and the significant increase in the average 12-month price target over the past month indicate a bullish sentiment for Tempest Therapeutics stock. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100